- AYTU Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Aytu BioPharma (AYTU) CORRESPCorrespondence with SEC
Filed: 30 Nov 17, 12:00am
AYTU BIOSCIENCE, INC.
373 Inverness Parkway, Suite 206
Englewood, CO 80112
November 30, 2017
Via Edgar
Division of Corporate Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Christine Westbrook | ||
Re: | Aytu Bioscience, Inc. | ||
Registration Statement on Form S-3 | |||
Filed November 22, 2017 | |||
File No. 333-221735 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Aytu BioScience, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Daylight Time, on Friday, December 1, 2017, or as soon thereafter as possible.
The Company acknowledges the following:
· | should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; |
· | the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
· | the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
Very truly yours, | ||
AYTU BIOSCIENCE, INC. | ||
By: | /s/Joshua R. Disbrow | |
Joshua R. Disbrow Chief Executive Officer |